Prime Medicine: Capital Increase Accompanied by Insider Buying - Board Invests Nearly $10 Million

Prime Medicine Inc. (PRME) launched a public stock offering at the end of July 2025 and successfully completed it on August 1 to secure the financing of its pipeline. A total of 43,700,000 common shares were sold at a price of $3.30 per share. This total includes the full exercise of the underwriters' option for an additional 5,700,000 shares. The Cystic Fibrosis Foundation purchased 1,818,181 of these shares without deductions or commissions, highlighting the company's close collaboration with the foundation. Through the offering, Prime Medicine...